“These exciting data suggest that the addition of a calcium channel blocker to gemcitabine may have some benefits, especially since calcium channel blockers have a very favorable toxicity profile, are low cost and are readily available,” said Thao Pham, PhD, research assistant professor of Medicine in the Division of Hematology and Oncology and a co-author of the study. Hidayatullah Munshi, MD, the Robert and Lora Lurie Professor of Medicine, was also a co-author of the study. Read more . . .
Calcium channel blockers may improve treatment for pancreatic cancer patients receiving gemcitabine-based chemotherapy, according to recent findings published in the Proceedings of the National Academy of Sciences.